Abstracts | 25 each). MB test was applied 30 min after i.p. drug administrations. In the marble burying test, 20 glass marbles, each about 4 cm apart, are arrayed on the surface of 5 cm thick sawdust bedding. The number of marbles buried (to 2/3 their depth) in a 30 min session were counted. Open field test was also conducted for locomotor activity. One-way analysis of variance (ANOVA) was used for statistical analysis followed by Tukey's test. Results: The number of marbles buried was not significantly different in agmatine (p>0.05) or ketamine (p>0.05) alone groups compared to control. When combined together in the same dosage regimen, the number of marbles buried was statistically less than control group (p<0.05). Conclusions: When administered alone at sub-effective doses, neither ketamine nor agmatine reduced compulsive-like behaviors. However, the combination of them resulted in potantialization in anticompulsive-like effects. It could be of interest to identify shared or distinct mechanisms of these molecules possibly responsible for the proposed behavioral manifestation seen in this compulsive model.
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Common variants of 5-HT3 receptor genes are associated with obsessive-compulsive disorder and its phenotypic expression 
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Abstract Objective: Evidence in the extant literature has indicated associations between serotonin-related genetic variants and obsessive-compulsive disorder (OCD), but few studies have explored the involvement of serotonin receptor type 3 genes in OCD. The present study aimed to identify whether HTR3 genetic variants may affect susceptibility to OCD. Methods: Ten common HTR3 variants were examined in 596 individuals with OCD and 599 controls. Single-marker association and haplotype-based association analyses were conducted regarding the affected status and different OCD sub-phenotypes, such as age at onset and clinical symptom dimensions. The impact of HTR3 variants on trait disgust sensitivity was also analyzed. Results: A significant difference in the genotype distribution of rs1176744 was detected between individuals with OCD and controls (odds ratio (OR) = 0.74, 95% confidence intervals (CI) = 0.60-0.91, p = 0.0044). A two-marker composite haplotype in HTR3B was also associated with OCD (OR = 0.77, CI = 0.63-0.95, permutated p = 0.0185). On analyzing clinical characteristics of OCD, significant associations were found for rs3758987 with age at onset in male subjects (OR = 0.49, CI = 0.30-0.78, p = 0.0025) and for rs6766410 and rs6443930 with the contamination/cleaning dimension in female subjects (OR = 0.36, CI = 0.18-0.69, p = 0.0017 and OR = 0.47, CI = 0.29-0.78, p = 0.0029, respectively). In addition, rs6766410 was significantly related to contamination-based disgust scores in the whole OCD sample (p = 0.0045). 
Conclusions

Abstract
Background: OCD has a strong genetic component, is highly comorbid with MDD, and is often triggered by stress. Genetic and epigenetic variation in SKA2 has been implicated in mediating stress response, and has recently been associated with suicidal behavior in MDD (Kaminsky, 2014). The SKA2 polymorphism rs7208505 exhibits allele-specific methylation. We hypothesized that genetic and epigenetic variation at SKA2 may play a role in OCD disease risk and severity. Methods: A sample of n=64 OCD patients, divided equally by presence/absence of comorbid MDD, and age and gender matched, were selected. Y-BOCS score was used to measure disease severity. Genotypes for rs7208505 were compared to Caucasian controls (n=379, 1000 Genomes Project) using Fisher's Exact test. The relationship among the rs7208505 variant, OCD disease severity, and MDD status was analyzed using ANCOVA. DNA methylation levels were quantified using bisulfite pyrosequencing. Pearson's r was used to investigate the correlation between percentage methylation and OCD symptom severity. Results: The SKA2 rs7208505 genotypes significantly differed between OCD patients and controls (χ 2 =10.21, p=0.006). The CC genotype was significantly associated with lower symptom severity than the CT/TT genotypes (F(3,52)=4.709, p=0.006). Percent methylation was negatively correlated with OCD severity (r=-0.438, n=56, p=0.001). Neither genetic nor epigenetic variation of rs7208505 was associated with comorbid MDD status. Conclusions: These results provide some evidence that SKA2 genetic and epigenetic variation may be a predictor of OCD risk and severity, regardless of MDD comorbidity; however, replication in larger samples is required. Further work will include interrogating additional genetic and epigenetic variations in SKA2.
